Status:
COMPLETED
The Role of Endothelin in Pulmonary Hypertension
Lead Sponsor:
Brigham and Women's Hospital
Conditions:
Pulmonary Hypertension
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
The purpose of the study is is to determine the effect, on the lung circulation, of BQ-123, an investigational compound which is not approved by the FDA.
Detailed Description
Endothelin levels are increased in patients with pulmonary hypertension. We wish to compare the effect of an endothelin antagonist on pulmonary hypertension due to a variety of causes.
Eligibility Criteria
Inclusion
- Healthy volunteers or known diagnosis of pulmonary hypertension
Exclusion
- hypertension due to other reasons (not pulmonary)
Key Trial Info
Start Date :
February 1 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00759408
Start Date
February 1 1999
End Date
June 1 2011
Last Update
November 27 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115